Navigation Links
HIV RNA Level Seen As Little Value In Predicting Treatment

A study in the September 27 issue of JAMA says that initial research indicates that the HIV RNA level in untreated HIV positive patients has little or no effect on CD4 cell count decrease. //This finding may lead to conflicts in opinion as to when antiretroviral therapy must begin.

Depletion of CD4 cells is a characteristic of progressive human immunodeficiency virus (HIV) disease and a powerful predictor of the short-term risk of progression to AIDS, according to background information in the article. Blood levels of HIV are also thought to predict HIV disease progression risk. In addition to their role as predictors of the clinical outcomes of HIV infection, CD4 cell count and plasma HIV RNA level are commonly used as markers of the success of highly active antiretroviral therapy (HAART). Until this study was completed, however, the degree to which blood levels of HIV could predict the rate of CD4 cell loss in HIV-infected individuals with similar demographic characteristics to those seen in clinical practice was unclear.

To address this question, Benigno Rodríguez, M.D., of Case Western Reserve University, Cleveland, and colleagues conducted a study to estimate the extent to which presenting blood levels of HIV can account for or "explain" the rate at which CD4 cells are depleted among an untreated HIV-infected population of patients including women and ethnic minorities. The study included repeated analyses of 2 multicenter groups, with observations beginning in May 1984 and ending in August 2004. Analyses were conducted between August 2004 and March 2006.

The participants included antiretroviral treatment–na?ve, chronically HIV-infected persons (n = 1,289 and n = 1,512 for each of the 2 groups) who were untreated during the observation period (6 months or greater) and with at least 1 HIV RNA level and 2 CD4 cell counts available. Approximately 35 percent were nonwhite, and 35 percent had risk factors other than male-to-male sex ual contact.

The researchers found that only a small proportion of the rate at which CD4 cells are lost (only 4 percent - 6 percent) in a given individual patient could be explained by presenting plasma HIV RNA level, suggesting that in chronic untreated HIV infection over 90 percent of the determinants of CD4 cell decline are not reflected in the amount of virus in blood at the time of initial medical evaluation.

"Our findings confirm previous observations that the magnitude of HIV viremia [the presence of a virus in the blood stream], as defined by broad categories of presenting HIV RNA level, is associated with the rate of CD4 cell loss and extend this observation to patient populations comprising both men and women. Despite this association, however, only a small proportion of the interindividual variability in the rate of CD4 cell decline can be explained by plasma HIV RNA level, even after accounting for the effect of measurement error," the authors write.

"These findings represent a major departure from the notion that plasma HIV RNA level is a reliable predictor of rate of CD4 cell loss in HIV infection and challenge the concept that the magnitude of viral replication (at least as reflected by plasma levels) is the main determinant of the speed of CD4 cell loss at the individual level. The clinical implications are that in the majority of cases, an individual patient's plasma HIV RNA level at the time of presentation for clinical care cannot predict, to a significant extent, the rate of CD4 cell decline that he or she will experience over the subsequent years and is therefore of limited clinical value in shaping the decision to initiate antiretroviral therapy," the researchers write.

Source-Eurekalert
RA
'"/>




Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Levels Of Blood Proteins May Help Heart Disease Care
3. Elevated Ozone Levels Hurt Sperm Count
4. Elevating Manganese Levels hold back HIV
5. High Levels of Protein Linked to Brain Shrinkage
6. Fitness Level Predicts Stroke
7. Chickens Found To Have High Levels of Arsenic
8. Low Protein Levels A Possible Indicator For A Miscarriage
9. Low Testosterone Levels the Cause Of Depression In Men
10. Weather Found To Play An Important Role In Cholesterol Levels
11. Education Levels Found To Predict Stress
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... For over twenty-four years, Doctors on Liens ... personal injury victims find high quality medical care. When the company started in 1997, ... Fast forward to present day and the now ten-page directory features a vast array of ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to host ... other developmental disabilities. The group, which is being launched with the help of Robbie ... share stories and advice, seek help, and continue their education on how to best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... MARLBOROUGH, Mass. , Dec. 2, 2016 ... announced a definitive agreement to acquire certain manufacturing assets ... NVCN ) (TSX: NVC) advanced biological tissue business, as ... a total of $75 million in cash. The Neovasc ... heart valves, including the Boston Scientific Lotus™ Valve System. ...
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
Breaking Medicine Technology: